Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,162
  • Shares Outstanding, K 1,150
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,850 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 2.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +333,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +85.50%
on 03/04/25
4.60 -19.35%
on 03/19/25
+0.48 (+14.86%)
since 02/21/25
3-Month
2.00 +85.50%
on 03/04/25
9.50 -60.95%
on 02/14/25
-1.69 (-31.30%)
since 12/20/24
52-Week
2.00 +85.50%
on 03/04/25
975.00 -99.62%
on 03/28/24
-874.79 (-99.58%)
since 03/21/24

Most Recent Stories

More News
CNS Pharmaceuticals (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company focused on treatments for brain and central nervous system cancers, provided an update on its cash position and efforts to maintain its Nasdaq...

CNSP : 3.71 (+2.49%)
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Cash on hand provides over one year of runway to fund expected operations

CNSP : 3.71 (+2.49%)
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the 18th Annual European Life Sciences CEO Forum in Zurich on Feb. 26, 2025, at 3:20 p.m. CET / 9:20 a.m. EST; management...

CNSP : 3.71 (+2.49%)
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor Top 5 for ‘25 On-Demand Conference, where CEO John Climaco outlined five key reasons for investors and industry...

CNSP : 3.71 (+2.49%)
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Webcast presentation Wednesday, February 26th at 3:20 PM CET

CNSP : 3.71 (+2.49%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit, taking place Feb. 18-20, 2025, in Boston. Chief Medical Officer Dr. Sandra Silberman will...

CNSP : 3.71 (+2.49%)
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here

CNSP : 3.71 (+2.49%)
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

- Access video webcasts from the first wave of participating companies here

AKTX : 1.5300 (+2.00%)
AREC : 0.5000 (+13.12%)
OTLK : 1.5100 (+2.03%)
AMIX : 1.99 (-9.13%)
CNSP : 3.71 (+2.49%)
PALI : 0.7108 (-9.28%)
NVNO : 2.98 (+2.76%)
HURA : 3.33 (-16.75%)
GRI : 8.27 (+18.14%)
CNS Pharmaceuticals Announces Reverse Stock Split

HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for...

CNSP : 3.71 (+2.49%)
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for...

CNSP : 3.71 (+2.49%)

Business Summary

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is...

See More

Key Turning Points

3rd Resistance Point 4.23
2nd Resistance Point 4.02
1st Resistance Point 3.86
Last Price 3.71
1st Support Level 3.49
2nd Support Level 3.28
3rd Support Level 3.12

See More

52-Week High 975.00
Fibonacci 61.8% 603.31
Fibonacci 50% 488.50
Fibonacci 38.2% 373.69
Last Price 3.71
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar